POAI - MCAP CO - Predictive Oncology

Predictive Oncology (POAI) maintains stable management and is successfully implementing AI systems into the validation of oncology drugs, although the business remains heavily dependent on external cloud services and clinics. The price visualization on GURU.Markets, which assists in the basic asset valuation, captured a value of . Predictive Oncology (POAI) minimizes biotech risks by creating digital models for pharma behemoths and generates revenue by providing specialized IT software for the fight against cancer.

Investors often seek ways to protect capital from the high volatility of small-cap companies. The implementation of sustainable AI algorithms at Predictive Oncology (POAI) confirms the business's commitment to long-term stability. This indicator reflects the aggregate value of all shares, determining the issuer's current market capitalization class. Analyzing the market value of all the company's outstanding shares allows for an assessment of liquidity and the fundamental scale of the business. The dynamics of this metric serve as a primary filter when calculating portfolio risks.